SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InforMax (inmx)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Paul Lee who started this subject5/21/2001 10:03:23 AM
From: Paul Lee   of 18
 
InforMax Announces GenoMax(TM) License Agreement With the University of North Carolina System


BETHESDA, Md., May 21 /PRNewswire/ -- InforMax, Inc. (Nasdaq: INMX), a leading global provider of bioinformatics software solutions, today announced that in the first quarter ending March 31, 2001 it signed a license agreement with the 16-campus University of North Carolina for GenoMax(TM) enterprise software.

(Photo: newscom.com )

Rapidly becoming an industry standard, GenoMax is an enterprise bioinformatics system that supports High-Throughput Research(TM) (HTR), InforMax's process for minimizing the time and cost of both discovering and validating valuable targets for pharmaceutical, therapeutic, and diagnostic development. GenoMax is a modular family of tools, each designed specifically to work with one or more types of genomic and proteomic data, including sequence information, gene expression data, and protein structure. InforMax expects to release GenoMax's Protein-Protein Interaction and Genome Analysis modules each in the second quarter of 2001. The GenoMax enterprise platform is used by more than 30 biopharmaceutical companies worldwide to leverage InforMax's data mining and analysis capabilities.

"Genomics and bioinformatics have emerged as areas of strategic economic importance to North Carolina," said UNC President Molly Corbett Broad. "While UNC-Chapel Hill and North Carolina State University -- our two research institutions -- have been leaders in these fields, we are pleased that this licensing agreement will now provide students and faculty on all 16 UNC campuses with exposure and access to the world-class bioinformatics tools and data bases found in GenoMax. We are hopeful that ready access to such rich resources will foster more interinstitutional research collaboration and technology transfer, strengthen related academic programs across the University, and help ensure a highly trained workforce for the state's growing biotechnology industry."

"We are pleased that the University of North Carolina has chosen GenoMax and our High-Throughput Research approach," said Alex Titomirov, Ph.D., InforMax chief executive officer and chairman. "GenoMax's collaborative capabilities are particularly well-suited to organizations such as UNC, where data sharing among remote locations is key to achieving research goals."

About The University of North Carolina

The oldest public university in America, the University of North Carolina today encompasses all 16 of North Carolina's public institutions that grant baccalaureate degrees and enrolls more than 163,000 students. UNC campuses support a broad array of distinguished liberal-arts programs, two medical schools and one teaching hospital, two law schools, a veterinary school, a school of pharmacy, ten nursing programs, 15 schools of education, three schools of engineering, and a specialized school for performing artists.

About InforMax

InforMax (Nasdaq: INMX) is a leading global developer of bioinformatics software for High-Throughput Research(TM). Founded in 1990, today InforMax products are used by 1,870 research organizations and more than 25,000 individual scientists worldwide (as of March 31, 2001) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution. Among the Company's customers are 23 of the top 25 pharmaceutical companies. The Company's mission is to support the scientific community in drug discovery and to better understand the causes of disease. Our High-Throughput Research(TM) and comprehensive suite of bioinformatics software solutions help scientists increase the effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover effective treatments for disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI(R) Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax (TM) for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the Company's Web site at informaxinc.com .
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext